Post‑traumatic stress disorder (PTSD) is thought to impact around 1 in 10 of us in our lives1 and can be difficult to treat. Although traditional therapies such as cognitive behavioural therapy (CBT), exposure therapy, Eye Movement Desensitisation and Reprocessing (EMDR), and selective serotonin reuptake inhibitors (SSRIs) offer relief for many, not everyone has positive responses.
In recent years, the therapeutic landscape has been transformed by a surge of scientific interest in psychedelic‑assisted therapy, particularly involving psilocybin. These emerging approaches are reshaping our understanding of trauma recovery and may soon expand treatment options in profound ways.
Why Psychedelics? Understanding the Scientific Breakthroughs
Growing research suggests that psychedelics work by enhancing neuroplasticity (the brain’s ability to reorganise and form new connections). Studies from 2026 reveal that psychedelic treatments may help repair disrupted brain networks by stimulating myelin remodelling, a key process in neural communication. These findings indicate that substances like psilocybin may help stabilise neural circuits damaged by trauma, supporting more sustained recovery2.
Further evidence shows these substances may help “rewire” the brain by restoring neural flexibility and reducing the overactive fear responses typical in PTSD. Early findings from neuroscience research highlight that psychedelics could help the brain unlearn fear while relearning safety, a critical step in long‑term symptom remission3.
Psilocybin Therapy: Rapid Progress in Clinical Trials
Psilocybin research is advancing just as quickly. Recent phase 2 clinical trials have found that a single 25 mg dose of psilocybin, combined with psychological support, can lead to rapid symptom reductions lasting up to 12 weeks. These trials reported no serious adverse events and showed significant improvements in the patients’ quality of life3.
Clinical trials are already underway in the Northwest of England exploring a psilocybin‑derived compound as a potential treatment for PTSD. These ongoing studies aim to clarify psilocybin’s long‑term safety, optimal dosing strategies, and the role of psychotherapy in enhancing outcomes.
A New Approach with Careful Considerations
While psychedelics hold tremendous promise, experts caution that they must be administered in controlled clinical settings with trained professionals. The patient’s mindset and therapeutic environment (known as “set and setting”) significantly influence treatment outcomes, underscoring the importance of structured, evidence‑based protocols.
Jacob, Psychedelic and Clinical Ratings Specialist at MAC Clinical Research, said: “At MAC, our clinical research facilitators are trained to navigate this complexity. With expertise in pharmacology, set and setting principles, and communication, they ensure participant safety and data integrity across diverse protocols, positioning MAC as a leader in flexible, high-quality psychedelic research.”
Clinical Trials for PTSD
MAC is looking for participants like you to help find more effective treatments for PTSD. We are currently investigating a psychoactive medication derived from psilocybin (the active ingredient in magic mushrooms), which could lead to changes in mood and perception and could help alleviate symptoms of PTSD.
If eligible, you will receive up to £1,680 for your time and commitment, plus travel expenses or transport for visits. Find out more on our PTSD research webpage.
1 PTSD UK – Post Traumatic Stress Disorder stats and figures
2 Medical Xpress – Psychedelics may aid PTSD recovery by repairing brain myelin, study finds
3 Live Science – Psychedelics may rewire the brain to treat PTSD. Scientists are finally beginning to understand how.
3 Compass Pathways – Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
